Utility of Adaptive Strategy and Adaptive Design for Biomarker-facilitated Patient Selection in Pharmacogenomic or Pharmacogenetic Clinical Development Program-Reference-Cited by-同舟云学术

Utility of Adaptive Strategy and Adaptive Design for Biomarker-facilitated Patient Selection in Pharmacogenomic or Pharmacogenetic Clinical Development Program

Published:2008-12 Issue:12 Volume:107 Page:S19-S27
ISSN:0929-6646
Container-title:Journal of the Formosan Medical Association
language:en
Short-container-title:Journal of the Formosan Medical Association

Author:

Wang Sue-Jane

Publisher

Elsevier BV

Subject

General Medicine

Reference15 articles.

1. Genomic biomarker derived therapeutic effect in pharmacogenomics clinical trials: a biostatistics view of personalized medicine;Wang;Taiwan Clinical Trials,2006

2. Use of genomic signatures in therapeutics development in oncology and other diseases;Simon;Pharmacogenomics J,2006

3. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI;Wang;Pharm Stat,2007

4. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med,2004

5. Optimal two-stage genotyping designs for genome-wide association scans;Wang;Genet Epidemiol,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure?;The Pharmacogenomics Journal;2019-10-17

2. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations;Pharmaceutical Statistics;2019-07-03

3. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review;PLOS ONE;2016-02-24

4. Statistical issues in quality control of proteomic analyses: Good experimental design and planning;PROTEOMICS;2011-02-07

5. Improving Dose-Finding;Handbook of Adaptive Designs in Pharmaceutical and Clinical Development;2010-10-25